Compare Crown Castle International Corp (CCI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crown Castle International Corp vs Sana Biotechnology Inc — how do they compare? Crown Castle International Corp trades at $73.89 (market cap $31.33B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Crown Castle International Corp is far larger — about 27.7× Sana Biotechnology Inc's market cap, and Crown Castle International Corp pays a 5.77% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| CCI | SANA | |
|---|---|---|
Market Cap | $31.33B | $1.13B |
Sector | Real Estate | Health |
52-Week High | $103.79 | $5.92 |
52-Week Low | $73.61 | $2.68 |
Enterprise Value | $53.69B | $1.05B |
Dividend Yield | 5.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Crown Castle (CCI) trades at $74.06, up 0.61% today, near a one-year low. The stock shows a bearish technical trend but maintains a 5.5% dividend yield. Recent Q2 2026 earnings beat AFFO estimates, with organic growth of 3.9%, though revenue declined year-over-year. The company completed its transition to a pure-play U.S. tower operator after selling its fiber business.
Outlook is mixed: analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting 29% upside. Key risks include high debt levels (debt-to-asset ratio of 77.21% in 2025) and competitive pressure in the tower REIT sector. The current valuation appears discounted relative to historical multiples, offering potential for income-focused investors.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
